EARLY WARNING DIAGNOSTICS FOR EMERGING INFECTIOUS DISEASES

AUGUST 29-30, 2022

Saurabh Mehta, M.B.B.S., Sc.D.
Janet and Gordon Lankton Professor
Global Health, Epidemiology, and Nutrition

Director, Center for Precision Nutrition and Health
Associate Director, PAHO/WHO Collaborating Center for Nutrition and Research for Health

Division of Nutritional Sciences | College of Human Ecology
Department of Population Health Sciences | Weill Cornell Medicine
Cornell University
<table>
<thead>
<tr>
<th>AFFILIATION/FINANCIAL INTERESTS (prior 12 months)</th>
<th>ENTITIES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grants/Research Support</td>
<td>National Institutes of Health (NICHD, NIBIB)</td>
</tr>
<tr>
<td></td>
<td>National Science Foundation</td>
</tr>
<tr>
<td></td>
<td>US Department of Defense</td>
</tr>
<tr>
<td></td>
<td>Global Alliance for Improved Nutrition</td>
</tr>
<tr>
<td></td>
<td>United States Department of Agriculture</td>
</tr>
<tr>
<td></td>
<td>United States Agency for International Development</td>
</tr>
<tr>
<td></td>
<td>HarvestPlus/International Food Policy Research Institute</td>
</tr>
<tr>
<td></td>
<td>World Health Organization</td>
</tr>
<tr>
<td>Scientific Advisory Board/Consultant/Board of Directors</td>
<td>VitaScan</td>
</tr>
<tr>
<td>Speakers Bureau</td>
<td>N/A</td>
</tr>
<tr>
<td>Owner/Stock Shareholder</td>
<td>VitaScan</td>
</tr>
<tr>
<td>Employer</td>
<td>Cornell University</td>
</tr>
<tr>
<td>Other</td>
<td>N/A</td>
</tr>
</tbody>
</table>
OUTLINE

1. Disclosure
2. Early Warning Diagnostics
3. Examples from our work
4. FeverPhone as an Example of plug and play systems
5. Key Messages and Challenges
Early Warning Diagnostics for Emerging Infectious Diseases in Developing into Late-Stage Pandemics

Published as part of the Accounts of Chemical Research special issue “Advances in Biosensor Technologies for Infection Diagnostics”.

Taylor M. Oeschger, Duncan S. McCloskey, Rose M. Buchmann, Aakash M. Choubal, Juan M. Boza, Saurabh Mehta, and David Erickson*
Figure 1. Timeline depicting point of implementation for various early warning systems

Figure 2. (A) Examples of sentinel animals and the corresponding human diseases they can be used to monitor. (B) Sample technology for microfluidic biochip for detecting Lyme antigens from sentinel animals using silver reagent precipitate and gold conjugated antibodies. Reproduced with permission from ref (25). Copyright 2016 Springer Nature

Figure 3. Graphical representation of detecting the SARS-CoV-2 virus in wastewater 1 to 2 weeks prior to the medically confirmed cases of COVID-19 in Gandhinagar, India. Reproduced with permission from ref (40). Copyright 2021 Elsevier Ltd.

Figure 4. (A) Common systems for capturing bioaerosols. Reproduced with permission from ref (45) Copyright 2019 Springer Nature. (B) Bioaerosol samplers: (1) SKC impinger BioSampler, (2) Coriolis cyclone sampler, (3) SKC BioStage Impactor, and (4) SKC button filter sampler. Reproduced with permission from ref (50). Copyright 2016 Elsevier Ltd.

Figure 5. (A) Portable energy flexible isothermal nucleic acid amplification device for the field screening of viral diseases, shown here powered by flame and sunlight. Reproduced with permission from ref (1) Copyright 2018 Springer Nature. (B) Sample technology for label-free optofluidic sensing of viruses with the corresponding light transmission profile readout. Reproduced with permission from ref (69). Copyright 2010 American Chemical Society. (C) Examples of detection methods for electrochemical biosensors for bacterial (1) cell-secreted electroactive metabolites, (2) electroactive enzymatic products, (3) impedance from mediated electron transfer, and (4) surface dielectric properties. Reproduced with permission from ref (66) . Copyright 2020 American Chemical Society.

PATHOGEN X: FEVERPHONE

- COVID-19 Ag and IgG/IgM tests
- Dengue Virus Infection
- Malaria
- Chikungunya Virus
- Zika Virus
- Chagas
- Inflammation markers PCT/CRP

FeverPhone platform - includes a portable low-cost reader, mobile app for guiding the user and data handling, a custom-designed test strip for the infectious disease of interest
Colorimetric Differential Detection of Dengue and Chikungunya Viral Infections

Architecture of multiplex lateral flow test strip. Red and blue nanoparticle conjugates are able to bind to DENV and CHIKV antibodies present in the sample, respectively.

Test strip results for human samples from colorimetric data. Samples were tested in random order and in duplicate, and average test line intensities are shown as individual data points grouped by ELISA positive/negative classification. The optimal intensity cutoff, as subsequently determined through ROC curve analysis is represented by the horizontal dotted line.

Two-Color Duplex Platform for Point-of-Care Differential Detection of Malaria and Typhoid Fever

Schematics of a typhoid/malaria duplex LFA

Calibration curve for LPS antigens with concentrations from 5 to 500 ng/mL.

Calibration curve for pLDH antigens with concentrations from 5 to 500 ng/mL.

COVID-19 Antigen and IgG/IgM test on FeverPhone platform

- **Detect IgG, IgM and antigen (Ag)**
  Overall screening of COVID-19 covering both acute and convalescence stages of infection

- **Rapid, Reliable**
  Time to result ~ 15 min
  > 90% sensitivity/specificity

- **All inclusive kit**
  Whole blood/serum
  No other equipment required
  Highly portable size, weight

- **Mobile App**
  User friendly guidance to run test
  Data management

- **Portable Reader**
  High resolution fluorescence imaging eliminates subjective interpretation of test results

**Features of RAPID COVIDx screening technology at point of care.**

Validation with clinical samples in progress at Ecuador field site. Comparison of three types of nanoparticles as label for lateral flow assay.
1. Predictive technologies and animal monitoring can help identify areas of high risk, whereas non-invasive testing can occur at the community level, before minimally invasive individual and group sampling is required.

2. Point of care diagnostic technology increases surveillance capacity in primary health care centers, low-economic status and remote areas.

3. Technologies for human and animal health monitoring could be integrated with other surveillance systems at the community, country and global level to identify early warnings and vulnerable populations.

4. This combination approach offers a framework for monitoring and minimizing potential infectious disease spread, ultimately reducing the tangible and intangible burdens of a future pandemic.
CHALLENGES

1. Point of care and other predictive technologies face adoption barriers such as regulatory approvals and policy development that allows local use outside of the research framework

2. Improve capacity for both development and manufacturing globally
THANK YOU + ACKNOWLEDGMENTS